Pluristem Therapeutics (PSTI) Announces Completion of PLX-PAD Phase 2 Enrollment
Tweet Send to a Friend
Pluristem Therapeutics Inc. (Nasdaq: PSTI) announced it has completed the planned enrollment of 150 patients in a global Phase II ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
